Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
349 EUR | +0.72% | -7.18% | -2.92% |
Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated | |
Apr. 17 | Virbac: sales up by almost 10% in Q1 | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm trades with high earnings multiples: 23.89 times its 2023 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.92% | 3.12B | B- | ||
-19.73% | 72.39B | B+ | ||
-11.01% | 6.54B | B- | ||
+15.88% | 3.43B | B- | ||
-0.68% | 1.4B | - | ||
-17.27% | 1.34B | B | ||
-2.73% | 1.26B | - | ||
-14.67% | 1.12B | - | ||
-5.37% | 990M | - | ||
-24.06% | 805M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VIRP Stock
- Ratings Virbac